Biliary tract cancers (BTC) are frequently identified at late stages and have a poor prognosis due to limited systemic treatment regimens. For more than a decade, the combination of gemcitabine and cis-platin has served as the first-line standard treatment. There are few choices for second-line chemo-therapy. Targeted treatment with fibroblast growth factor receptor 2 inhibitors, neurotrophic tyrosine receptor kinase inhibitors, and isocitrate dehydrogenase 1 inhibitors has had important results. Immune checkpoint inhibitors (ICI) such as pembrolizumab are only used in first-line treatment for microsatellite instability high patients. The TOPAZ-1 trial's outcome is encouraging, and there are several trials underway that might soon put targeted treatment and ICI combos into first-line options. Newer targets and agents for existing goals are being studied, which may represent a paradigm shift in BTC management. Due to a scarcity of targetable mutations and the higher toxicity profile of the current medications, the new category of drugs may occupy a significant role in BTC therapies.
Keywords: Biliary tract cancers; Fibroblast growth factor receptor 2 inhibitors; Gemcitabine and cisplatin combination; Immune checkpoint inhibitors; Infrigatinib; Isocitrate dehydrogenase 1 inhibitors; Microsatellite instability high; Neurotrophic tyrosine receptor kinase gene fusion inhibitors; Pemigatinib.
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.